| 1 |
钱桂生. 肺癌不同病理类型发病率的变化情况及原因[J/CD]. 中华肺部疾病杂志(电子版), 2011, 4(1): 1-6.
|
| 2 |
杨玲，李连弟，陈育德，等. 中国肺癌死亡趋势分析及发病、死亡的估计与预测[J]. 中国肺癌杂志，2005, 8(4): 274-278.
|
| 3 |
Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung[J]. J Clin Oncol, 2012, 30 (10): 1122-1128.
|
| 4 |
Fukuoka M, Wu YL, ThongprasertS, et al. Biomarker analyses and final overall survival results from a phase Ⅲ，randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
|
| 5 |
Michael M, White SC, Abdi E, et al. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC[J]. Asia Pac J Clin Oncol, 2015, 11(1): 4-14.
|
| 6 |
Liang J, Ahn M, Kang J, et al. First-line treatment (txt) with pemetrexed-cisplatin (PC), followed sequentially by gefitinib (G) or pemetrexed, in Asian, never-smoker (n/smkr) patients (pts) with advanced NSCLC: An open-label, randomized phase Ⅱ trial[J]. J Clin Oncol, 2010, 28, 7591.
|
| 7 |
Choi YJ, Kim SW, Lee DH, et al. Paclitaxel/carboplatin (pc) intercalated with gefiinib or paclitaxel/carboplatin (pc) for advanced non-small cell lung cancer (nsclc) in selected population who were smoker or wild-type EGFR: randomized phase ii study[J]. J Clin Oncol, 2013, 31(15):e19079.
|
| 8 |
Arteaga CL. ErbB-targeted therapeutic approaches in human cancer[J]. Exp Cell Res, 2003, 284(1): 122- 130.
|
| 9 |
Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 50(21): 2129-2139.
|
| 10 |
Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304(5676): 1497-1500.
|
| 11 |
Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004, 64(24): 8919-8923.
|
| 12 |
Rizvi NA, Rusch V, Pao W, et al. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene[J]. Clin Cancer Res, 2011, 17(10): 3500-3506.
|
| 13 |
Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumours (TAILOR): a randomized controlled trial[J]. Lancet Oncol, 2013, 14(10): 981-988.
|
| 14 |
Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs[J]. JAMA, 2014, 311(19): 1998-2006.
|